Text Size

Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

This study is currently recruiting participants.
Verified January 2013 by University of Arkansas
Sponsor:
Information provided by (Responsible Party):
University of Arkansas
ClinicalTrials.gov Identifier:
NCT01622582
First received: June 15, 2012
Last updated: January 7, 2013
Last verified: January 2013
History of Changes
  Purpose

Engraftment Syndrome after Autologous Stem Cell Transplant: Retrospective Review in Patients with Multiple Myeloma


Condition
Multiple Myeloma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

Resource links provided by NLM:

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • number of patients developing Engraftment syndrome following stem cell transplant [ Time Frame: 6 months post-transplant ] [ Designated as safety issue: Yes ]
    A retrospective review where subjects medical records are studied for development of engraftment syndrome 6 months after stem cell transplant


Estimated Enrollment: 1200
Study Start Date: January 2006
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Detailed Description:

A retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with Multiple Myeloma, developing engraftment syndrome

Criteria

Inclusion Criteria:

  • Patients with Multiple Myeloma, developing engraftment syndrome

Exclusion Criteria:

  • Patients with Multiple Myeloma, with no features of engraftment syndrome
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01622582

Locations
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Naveen sanath kumar, MD, MHSA     501-681-1972     nsanathkumar@uams.edu    
Principal Investigator: Senu Apewokin, MD            
Sub-Investigator: Naveen Sanath Kumar, MD, MHSA            
Sponsors and Collaborators
University of Arkansas
Investigators
Principal Investigator: Senu Apewokin, MD UAMS
  More Information

No publications provided

Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT01622582     History of Changes
Other Study ID Numbers: UARK 2008-30
Study First Received: June 15, 2012
Last Updated: January 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arkansas:
Multiple Myeloma, Engraftment syndrome

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
 Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013